P. aeruginosa biofilms, which minimizes the entry of antimicrobial compounds inside bacterial cells and hinders the recognition of pathogen-associated molecular patterns (PAMPs) by the host immune system (Alhede et al., 2014) . .Consequently, current treatments against P. aeruginosa fail to resolve infections before tissue deterioration occurs. To address this concern, more efficient alternatives to abolish P. aeruginosa infections have produced promising but not definitive results. Accordingly, several candidate P. aeruginosa vaccines have been developed by targeting outer membrane proteins (Opr), lipopolysaccharides (LPS), polysaccharides (PS) as reported by Horn et al. (2010) , Kamei et al. (2011) , Campodonico et al. (2011) and Hilker et al. (2015) . Pseudomonas aeruginosa exopolysaccharide (Psl) is a serotypeindependent, antibody-accessible antigen that is prevalent among both nonmucoid and mucoid clinical isolates. Interestingly, monoclonal antibody (mAbs) that bound to one particular Psl epitope mediated potent opsonophagocytic killing of P. aeruginosa in vitro, inhibited bacterial attachment to cultured lung epithelial cells and provided potent prophylactic protection WAGIH EL-SHOUNY et al. in multiple animal models of P. aeruginosa infection. So that, Psl is a novel protective antigen and that antibodies targeting Psl might be an effective measure for prophylaxis against P. aeruginosa infections in high-risk patients (Hraiech et al., 2015; Emmanuelle et al., 2017 and Alessio et al., 2017) . This paper concerns with the enhancement of the immune response in mice induced by exopolysaccharides produced by different strains of Pseudomonas syringae against human pathogenic Pseudomonas aeruginosa.
Materials and Methods
Three strains of Gram-ve bacteria of Pseudomonas syringae (P. syringae pv. tomato, P. syringae pv. coriandericola 908, P. syringae davson 973 were studied for their alginate (EPS) protective efficacy against human pathogenic Pseudomonas aeruginosa.
Isolation of exopolysaccharides
Preparation of inoculum For inoculum preparation, two successive pre-cultures were grown. The growth was measured turbidemetrically at 660 nm in order to standardize the quantity of the bacterial cells used for inoculation throughout the experiments. The first pre-culture was prepared by suspending aloop of bacteria in about 30 ml of KW-medium (Keen & Williams, 1971) .
Production of exopolysaccharides 250 ml Eelenmeyer flasks were filled with 100ml of autoclaved medium and inoculated by 2% portion of the pre-culture of the experimental bacterium. The flasks were incubated at 37°C for 1 day in rotary shaker (120 rpm). At the end of the incubation period, the bacteria were pelleted by centrifugation and re-centrifugation at 6000 rpm. The clear supernatant was used for further investigations since it contained the crude Bacterial EPS.
Partial purification of exopolysaccharides
The culture supernatant was treated by the addition of trichloroacetic acid (TCA) 5% for removing protein according to Khalil (2002) and stored at freezer overnight. The supernatant was mixed with three volumes of 95% of ethanol, stirred vigorously overnight at 4°C. The resultant precipitate was recovered by centrifugation at 3000 rpm for 20 min (Wu et al., 2008) . Exopolysaccharides were estimated by phenol sulphuric assay (Dubois et al., 1956 ).
Blood counts
Total white blood cell counts It was done according to Kruse et al. (1973) Firstly, red blood cells were removed by lyses in diluted acid to prevent the erroneous counting of red blood cells as small lymphocytes. Total white blood cell counts were determined by addition of 0.01 % gentian violet in 3 % acetic acid (Turk`s solution) to facilitates counting since it stain the white blood cells.
Procedure
The appropriate dilutions of cell suspension prior to counting were made, the optimal concentration of cells was (50-100 cells per large square) after dilution in the counting solution, Pasteur pipette with finger control were used to lead the cell suspension flow under the cover slip until the grid area is just full, then all of the cells contained in each of the four large squares were counted, finally, the average number of the cells per large square must be determined by the following equation :
These were the number of cells per 4000 ml N :-Total number of leucocytes counted in the 16 large square
The leucocytes count in all large squares = 16
Number of dilution = 10
Differential white blood cell counts A blood film was treated by using Leishman stain, and the number of each type of leukocytes per field was recorded.
Mice immunization
Adult male mice, 6 to 8 weeks of age (weigh, 15 to 25 g) were housed on the basis of study requirements. Mice were divided into 12 groups (6 animals per cage), out of them, three groups were taken as control groups.Three of the EPS obtained from the three P.syringae pathovars were subjected to test on mice.
Mice lethal challenge
The bacterial challenge dose of Pseudomonas aeurginosa which caused > 90% mortality within 2 days was determined to be the lethal dose. The bacterial challenge for the subsequent experiments was prepared as follows; P. aeurginosa was grown overnight (18 -24 h) on nutrient agar, the bacterial cells were collected and suspended in sterile N X 4000 X 10 16 X 16 phosphate-buffered solution (PBS). Bacterial cells were suspended to an optical density of 0.3 at 660 nm., corresponding to 10 8 CFU/ml as lethal dose, immediately before injection. Mice were challenged by administering intraperitoneal (i.p.) one ml of bacterial suspension. Non-immunized control mice were challenged with one ml of PBS (Fattom et al., 1996) .
Active immunization
Mice were immunized subcutaneouly (s.c) in first, second and third days with 1 ml of P. syringae EPS (divide into 3 doses). Animals were challenged intraperitoneal (i.p.) in fifth day with doses of P. aeurginosa 10 7 and 10 8 CFU/ml). A serum sample was obtained from each mouse after 5 days of the last immunization and the mice of control group injected s.c with PBS were also bled concurrently and challenged (Fattom et al., 1996) , blood samples were also collected from mice after bleeding for blood count (total and differential blood counts).
Mice were randomly selected and removed from cages at designated time points after challenge, selected mice were weighted, bled and evaluated for livers, spleens and lunges. Organs were excited, weighted, washed, with 70 % ethyl alcohol to eliminate surface-attached organisms, then washed with sterile PBS, and homogenized in 1 ml PBS. 0.1ml of this suspensions were cultured on King`B agar plates and bacteria were counted after overnight incubation and expressed as CFU per organ (Fattom et al., 1996) .
Results

Mice lethal challenge
In Table 1 , groups of non-immunized mice were injected intraperitoneally (i.p.) with different doses of virulent human pathogen P. aeruginosa ranged from 10 5 to 10 10 CFU/ mouse. It recorded that the bacterial challenge caused more than 75% mice mortality within two days of injection was 10 8 CFU/ mouse and sub-lethal dose was 10 7 CFU/ mouse. These doses were used for challenge in subsequent experiments. 
Effect of bacterial challenge on leukocyte count
Leukocyte counts of mice blood which infected only with P. aeruginosa, mice which immunized by bacterial EPS preparations and mice which immunized with bacterial EPS preparations and infected with P. aeruginosa 3 were presented in Table 2 . The results revealed that all groups of mice recorded an increase in total leukocyte counts as well as neutrophil and monocyte numbers if compared with saline control group.
Bacteremia
Data present in Table 3 show the effect of (ip) active immunization by purified bacterial EPS on the counts of P. aeruginosa in lungs, spleens and livers of challenged mice. The data revealed the protection of organs against bacteremia except group 7 and group 8 which recorded bacterial cells in their lungs, spleen and liver. Group 7 immunized with 1ml P. syringae pv. tomato EPS and challenged with 1ml of lethal dose (10 8 CFU/ mouse) recorded in lung 6 x 10³ CFU, in spleen 11 x 10² CFU and in liver ( two lobes ) was 34 x10² CFU. Group 8 immunized also with 1ml P. syringae pv. tomato EPS and challenged with 1ml of sub-lethal dose (10 7 CFU/ mouse) recorded in lung 5 x 10³ CFU, in spleen was 9 x 10² CFU and in liver ( two lobes ) was 32 x 10² CFU. If compared with control groups group 2 and group 3 which recorded bacterial counts more than group 7 and group 8. 
Discussion
In Table 1 , mice infection was accomplished by intraperitonial injection of the determined lethal dose of P. aeurginosa 10 8 CFU/ mouse). At these dose more than 85% of non-immunized mice were died within two days of injection and also recorded decreasing of mice weight. These results indicated the presence of bacterial infection which causes death. Similar results were obtained by Fattom et al. (1996) found that a dose of 2 x 10 5 CFU of S. aureus type 5 CP per mouse administrated intraperitoneally (i.p.) with 5% hog mucin was found to cause 80 to 100% mortality in BALB/c mice within 2-5 days. While mice actively immunized with the monovalent type 5 CP-P. aeruginosa exoprotein. showed a survival rate of 73% compared with 13% in phosphatebuffered saline-immunized animals. Similar results were found by El-Shouny (2000) who reported that the mortality rate reached >75 % within 2 days in mice after (i.p.) injection with 10 9 CFU/mouse with P. aeruginosa. Also, Allam & Elslik (2011) found that the use of lipopolysaccharide (LPS), exopolysaccharide (EPS) and mutant strain as subunit vaccines against intraperitoneal (I/P), challenge of Serratia marcescens W225 in mouse model referring to E. coli as standard, that elicit the secretions of IgM, which have protection role against lethal doses challenge, or their toxicity in mice through the follow up of liver enzymes, urea and weight. The results indicated that capsular or EPS and mutant strain (S. marcescens W1765) antigens (vaccines) confer the highest protective immunization. Table 2 , the total white blood cells and differential count included neutrophils and monocytes were increased due to the bacterial challenge and lymphocytes were decreased due to the bacterial infection. In accordance with their results, Santos et al. (2008) The obtained results from Table 3 revealed reduction of bacteremia as response of active immunization with 1 ml of intraperitoneal (i.p) injection of purified EPS on three successive doses before bacterial challenge with 1ml P. aeruginosa (s.c). Group of mice immunized with EPS from P. syringae pv. tomato was dead when challenged with lethal dose (10 8 CFU/ml) but when challenged with sub-lethal dose (10 7 CFU/ ml), the bacterial cells recorded in their lungs, spleens and livers were 5x10³, 9 x10² and 32x10² CFU/organ, respectively, when compared with control groups which recorded higher bacterial counts. However, other groups of mice were immunized with EPS from P. syringae davson 973 and P. syringae pv. coriandricola 908 had no bacterial cells recorded in their lungs, spleens and livers, after bacterial challenge with lethal dose and sub-lethal dose, respectively, These data suggested that the dose of Pseudomonas syringae pv. tomato EPS did not exhibit immunization but the doses" of P. syringae davson 973 and P. syringae pv. coriandricola 908 "EPS in successive doses enhanced the immune response to overcome the bacterial challenge and preventing seeding of organs with bacteria. This was in agreement with Hatcher et al. (2015) who found that the immunogenicity of the polyvalent O-polysaccharide-toxin A conjugate vaccine reflected lower frequency of P. aeruginosa in sputum/throat cultures and preservation of lung function. Also, Gamboa et al. (2009) found that when animals (red deer) received vaccine (alginate composite microspheres containing a nonimmunogenic, eggshell-precursor protein of the parasite Fasciola hepatica) exhibited significant reduction in bacterial counts in their spleens. El-Shouny (2000) proved the immunoprotective efficacy of Pseudomonas syringae pv. coriandricola exopolysac chride against Pseudomonas aeurginosa infection in mice. Finally, Laroussarie et al. (2015) suggested that Pseudomonas aeruginosa exopolysaccharide (Ps l) is a serotype-independent, antibody-accessible antigen that is prevalent among both nonmucoid and mucoid clinical isolates. Interestingly, monoclonal antibody (mAbs) that bound to one particular Ps l epitope mediated potent opsonophagocytic killing of P. aeruginosa in vitro, inhibited bacterial attachment to cultured lung epithelial cells and provided potent prophylactic protection in multiple animal models of P. aeruginosa infection. So that, Ps l is a novel protective antigen and that antibodies targeting Ps l might be an effective measure for prophylaxis against P. aeruginosa infections in high-risk patients (Laroussarie et al. (2015) ; Lei et al. ( 2016) and Van et al. ( 2017) .
As shown in
It could be concluded that the three tested EPSs were proven to be immunoprotective and prophylactic agents against P. aeruginosa infection in mice.
